KERX Financial Facts

Total research and development: 7.96M
Basic and diluted net loss per common share: -0.26
See Full Income Statement

Total liabilities: 30.02M
Goodwill: 3.21M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 11/6/15 *Est. EPS Growth Rate -8.3% *Last Qtr.
Average EPS % Beat Rate -13.2% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS -4.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/5/15 Q215 -$0.26-$0.26 $0.00$2.5M$2.86M N/A Details
5/4/15 Q115 -$0.28-$0.30 +$0.02$1.2M$2.45M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
8/7/14 Q214 -$0.24-$0.25 +$0.01N/AN/A N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details